Managing Bortezomib-Induced Neuropathy

In this article, we discuss a common and painful side effect associated with cancer treatment.

Recent Content

Exelixis and their partner Roche are seeking fast-tracked FDA approval for their combination therapy drug for people with BRAF V600 mutation-positive advanced melanoma.

A 45-year-old man presents with gastric pain and is found to have a gastric nodule. After further evaluation, a biopsy is performed. What is your diagnosis?

For women with triple-negative breast cancer (TNBC), adding bevacizumab (Avastin) to standard neoadjuvant chemotherapy was more beneficial for those diagnosed with basal-like tumors compared to those with nonbasal-like tumors. This data was presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), being held Dec. 9-13, 2014 in San Antonio.

On December 3, 2014, the U.S. Food and Drug Administration (FDA) announced the approval of Amgen's immunotherapy drug Blincyto (blinatumomab), a bispecific T-cell engager (BiTE) used to treat patients diagnosed with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL).

A 19-year-old woman presents with anterior cervical area lymphadenopathy. After further evaluation, a lymph node biopsy is performed. What is your diagnosis?

“This drug will save your life, but you have to take it every day.”I’m pretty sure it was said insensitively.    

In May 2012, the United States Preventive Services Task Force (USPSTF) released a recommendation against prostate-specific antigen (PSA) screening for men. The justification for this recommendation was that large randomized trials demonstrated that PSA screening increased detection of prostate cancer, but there was "small to no reduction in prostate cancer-specific mortality."

By clicking Accept, you agree to become a member of the UBM Medica Community.